Biogen

$265.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$6.52 (-2.40%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Biogen and other stocks, options, and ETFs commission-free!

About BIIB

Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. The listed name for BIIB is Biogen Inc. Common Stock.

CEO

Michel Vounatsos

Employees

7,400

Headquarters

Cambridge, Massachusetts

Founded

1978

Market Cap

40.00B

Price-Earnings Ratio

9.12

Dividend Yield

—

Average Volume

1.39M

High Today

$268.66

Low Today

$262.99

Open Price

$267.70

Volume

1.11M

52 Week High

$374.99

52 Week Low

$223.25

Collections

Analyst Ratings

36%

of 33 ratings

Buy

36%

Hold

48%

Sell

15%

BIIB Earnings

$0.00

$3.42

$6.84

$10.26

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Available Feb 3, Pre-Market